Stem Cell Clinic

Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma…

By Adult Stem Cells

Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis

Company Announcement

Copenhagen, Denmark; October 21, 2020 Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the second part of the Phase 3 CASSIOPEIA (MMY3006) study of daratumumab monotherapy as maintenance treatment versus observation (no treatment) for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant (ASCT). The second part of the study, which is being conducted by the French Intergroupe Francophone du Myelome (IFM) in collaboration with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen Research & Development, LLC (Janssen), met the primary endpoint of improving progression free survival (PFS) at a pre-planned interim analysis (Hazard Ratio (HR) = 0.53 (95% CI 0.42 0.68), p < 0.0001) resulting in a 47% reduction in the risk of progression or death in patients treated with daratumumab. The safety profile observed in this study was consistent with the known safety profile of daratumumab and no new safety signals were observed.

Based on the results at the pre-planned interim analysis conducted by an Independent Data Monitoring Committee (IDMC), it was recommended to unblind the study results. Janssen Biotech, Inc., which licensed daratumumab from Genmab in 2012, plans to discuss the potential for a regulatory submission for this indication with health authorities, and plans to submit the data to an upcoming medical conference and for publication in a peer-reviewed journal.

Following the positive data from the first part of the CASSIOPEIA study, we are very pleased to see this benefit. We are appreciative of the efforts of the IFM, of HOVON and of Janssen for their work on this study, said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

About the CASSIOPEIA (MMY3006) Study This Phase 3 study is a randomized, open-label, multicenter study, conducted by the IFM in collaboration with the HOVON and Janssen, which includes 1,085 newly diagnosed subjects with previously untreated symptomatic multiple myeloma who were eligible for high dose chemotherapy and ASCT. In the first part of the study, patients were randomized to receive induction and consolidation treatment with daratumumab combined with bortezomib, thalidomide and dexamethasone (VTd) or VTd alone. The primary endpoint was the number of patients that achieved a stringent complete response (sCR). In the second part of the study, patients that achieved a response underwent a second randomization to either receive maintenance treatment of daratumumab 16 mg/kg every 8 weeks for up to 2 years versus no further treatment (observation). The primary endpoint of this part of the study is progression free survival.

About Multiple Myeloma Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excess proliferation of plasma cells.1 Multiple myeloma is the third most common blood cancer in the U.S., after leukemia and lymphoma.2 Approximately 26,000 new patients were expected to be diagnosed with multiple myeloma and approximately 13,650 people were expected to die from the disease in the U.S. in 2018.3 Globally, it was estimated that 160,000 people were diagnosed and 106,000 died from the disease in 2018.4 While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed due to symptoms which can include bone problems, low blood counts, calcium elevation, kidney problems or infections.5

About DARZALEX(daratumumab) DARZALEX (daratumumab) has become a backbone therapy in the treatment of multiple myeloma. DARZALEX intravenous infusion is indicated for the treatment of adult patients in the United States: in combination with carfilzomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma who have received one to three previous lines of therapy; in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.6 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma.

DARZALEX is indicated for the treatment of adult patients in Europe via intravenous infusion or subcutaneous administration: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy7. Daratumumab is the first subcutaneous CD38 antibody approved in Europe for the treatment of multiple myeloma. The option to split the first infusion of DARZALEX over two consecutive days has been approved in both Europe and the U.S.

In Japan, DARZALEX intravenous infusion is approved for the treatment of adult patients: in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of relapsed or refractory multiple myeloma. DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United States, Europe and Japan. For more information, visit http://www.DARZALEX.com.

DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, is approved in the United States for the treatment of adult patients with multiple myeloma: in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for ASCT and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy; in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and as monotherapy, in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.8 DARZALEX FASPRO is the first subcutaneous CD38 antibody approved in the U.S. for the treatment of multiple myeloma.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. Daratumumab triggers a persons own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).6,9,10,11,12

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase 3 studies in smoldering, relapsed and refractory and frontline multiple myeloma settings. Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases in which CD38 is expressed, such as amyloidosis and T-cell acute lymphocytic leukemia (ALL). Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA for certain indications of multiple myeloma, including as a monotherapy for heavily pretreated multiple myeloma and in combination with certain other therapies for second-line treatment of multiple myeloma.

About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of the following approved antibodies: DARZALEX (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Kesimpta (subcutaneous ofatumumab, under agreement with Novartis AG), for the treatment of adults with relapsing forms of multiple sclerosis in the U.S. and TEPEZZA (teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A subcutaneous formulation of daratumumab, known as DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in the U.S., has been approved in the U.S. and Europe for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy, Arzerra (ofatumumab, under agreement with Novartis AG), approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody platform for generation of bispecific antibodies, the HexaBody platform, which creates effector function enhanced antibodies, the HexElect platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

Contact: Marisol Peron, Corporate Vice President, Communications & Investor Relations T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations: Andrew Carlsen, Senior Director, Investor Relations T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmabs most recent financial reports, which are available on http://www.genmab.com and the risk factors included in Genmabs most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at http://www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; HuMax; DuoBody; DuoBody in combination with the DuoBody logo; HexaBody; HexaBody in combination with the HexaBody logo; DuoHexaBody; HexElect; and UniBody. Arzerra and Kesimpta are trademarks of Novartis AG or its affiliates. DARZALEX and DARZALEX FASPRO are trademarks of Janssen Pharmaceutica NV. TEPEZZA is a trademark of Horizon Therapeutics plc.

1 American Cancer Society. "Multiple Myeloma Overview." Available at http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-what-is-multiple-myeloma.Accessed June 2016. 2 National Cancer Institute. "A Snapshot of Myeloma." Available at http://www.cancer.gov/research/progress/snapshots/myeloma. Accessed June 2016. 3 Globocan 2018. United States of America Fact Sheet. Available at http://gco.iarc.fr/today/data/factsheets/840-united-states-of-america-fact-sheets.pdf. 4 Globocan 2018. World Fact Sheet. Available at http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed December 2018. 5 American Cancer Society. "How is Multiple Myeloma Diagnosed?" http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-diagnosis. Accessed June 2016 6 DARZALEX Prescribing information, August 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761036s029lbl.pdf Last accessed August 2020 7 DARZALEX Summary of Product Characteristics, available at https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex Last accessed June 2020 8 DARZALEX FASPRO Prescribing information, May 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761145s000lbl.pdf Last accessed May 2020 9 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848. 10 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21. 11 Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94. 12 Jansen, JH et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking.Blood. 2012; 120(21): abstract 2974.

Continue reading here:
Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma...

Unless the country invests in cancer care, the statistics for breast cancer will be bleak: Dr Anthony Pais, .. – ETHealthworld.com

By Stem Cell Doctors

Representative image of a cancer cellBy Dr Anthony Pais, Senior Consultant and Clinical Director Oncoplastic Breast Surgery, Cytecare Hospitals, Yelahanka, Bengaluru

Striving for better prognosis & personalised care for breast cancer In India, there is a confirmed breast cancer diagnosis every four minutes, making it one of the top three types of cancers prevalent in the country. The COVID-19 pandemic has amplified the challenges of detection and treatment by pushing breast health awareness to a low priority.

The prime peril in the current scenario is that cancers are likely to be undetected until they reach stage 3 or 4, drastically cutting down the chances of recovery. While the treatment of breast cancer is covered under government schemes such as A yushman Bharat, the need of the hour is greater awareness and timely action.

New learnings Theres a lot more that we know about breast cancer today than we did a decade ago. Diagnostic scans are more accurate and radiation treatments come with lesser side-effects today. The development of immunotherapy and newer drugs for targeted treatment as well as breakthroughs in stem cell research and gene therapy are paving the way for effective and personalised cancer care in the future.

Recently, researchers at Lund University in Sweden published their findings on developing a computational model that effectively detects and identifies genetic mutations in breast tumours. Based on data gathered over 10 years from over 15,000 patients, the study, published in the scientific journal EMBO Molecular Medicine, aimed to inform patients a week after surgery which personalised treatment was best suited for them.

In terms of therapeutics, theres greater focus on molecular drivers of the cancer with multiple agents being developed for every subtype of breast cancer. Though still new to the immunotherapy space, there is exciting data emerging in breast cancer treatment, particularly with triple-negative breast cancer. There is a steady transitioning towards reduced surgeries and making radiation therapy more comprehensive for high-risk patients. By choosing to combine lumpectomy over mastectomy and fewer axillary surgeries, there is a decrease in the risk of lymphedema.

Studies show that physical activity and healthy diet, along with lifestyle changes, are important factors in influencing the health outcomes for women with breast cancer. Patients with ER-positive breast cancer on certain inhibitors, for instance, tend to gain weight and obese patients have poorer outcomes with therapy. In some cases, a low-fat diet and even as little as five per cent weight loss decreased the risk of recurrence.

Simple solutions A majority of healthcare centres in India lack the basic facilities for early diagnosis of cancer and adequate expertise to treat the disease in the most effective manner. Unless the country invests in cancer care, the statistics for breast cancer will continue to be bleak.

Theres no denying that technological advances in imaging are creating massive improvements in both screening and early detection. For instance, 3-D mammography, also called breast tomosynthesis, takes multiple images or X-rays of breast tissue to recreate a 3-dimensional picture of the breast.

However, as the latest World Cancer Report (2020) rightly states, the best way to tackle the challenge is by early detection through regular breast examination (self-examination as well as mammogram). For women above 40 years of age, regular breast examination with a mammogram is recommended once in two years.

The need of the hour is to spread awareness about the importance of getting breast examinations done. Its essential to design powerful campaigns to drive societal changes. In most parts of India, women are uncomfortable to discuss symptoms and go in for a physical examination. Studies show that most deaths occur among the unscreened population as the cancer is typically detected at a late stage.

The pandemic has forced the world to look at healthcare with renewed emphasis. Now is the time to make lasting changes for a healthier and happier life.

Read this article:
Unless the country invests in cancer care, the statistics for breast cancer will be bleak: Dr Anthony Pais, .. - ETHealthworld.com

How Clinique La Prairie Is Keeping Humanity Fashionably Healthy In The Age Of Covid – Forbes

By Stem Cell Doctors

MONTREUX, SWITZERLAND - the Clinique La Prairie facility

Fashion, beauty, health and wellness are all intertwined. You cant really have one without the other

The Clinique La Prairie (CLP) in Montreux, Switzerland has been purveyors of luxury health and wellness for 89 years. This is Switzerlands thing, and one of the main reasons why people travel to the scenic nation of wellness facilities, mountains and natural springs because the country knows and understands the value of health and wellness, especially in this time of Covid. There are facilities like CLP all over Switzerland, with expert and advanced care that offer an intimate luxury environment. For CLP, its their mission to partner with visitors by providing personalized treatment to help and inspire people to live longer, healthier and better lives.

Our vision is always looking at pioneering longevity, says Simone Gibertoni, the CEO of CLP. As the future of wellness is linked to epigenetics, genomics, mental wellness and many more inspiring sciences, we are also taking a particular interest in research on microbiota, senescent cells and their markers, stress and sleep, circadian rhythms- among other aspects of life science and biology, in an effort to determine how they can be used to promote holistic longevity. This approach is envogue and the most fashionable lifestyle implementation that an individual can make in an effort to promote self-longevity.

So, how has this facility overlooking Lake Geneva been able to carry on a mission and vision of world class wellness- with the aim of opening up CLP facilities in Bangkok and Madrid this year, and, other facilities throughout the Middle East, Asia and the Americas in the future? From its inception in 1931 by Professor Paul Niehans, who pioneered development cell therapy, CLP almost ninety years later has continued to expand due to top health and wellness innovations. With fifty specialists, wellness programs that range from immune-boosting and anti-aging revitalization, and luxury hospitality all combined in a state-of-the-art facility, the clinic has been able to grow after all this time and keep people living longer in the process.

MONTREUX, SWITZERLAND - the Clinique La Prairie facility

We believe that health is not only the absence of illness, but the balance of mind, spirit and body, continues Gibertoni.Our guests have the privilege of being accompanied and advised in the ultimate refinement, and benefit from the expertise of leading specialists, from renowned doctors to experts in sport, wellness, and nutrition.

Pioneering health and wellness in the age of covid

As CLP is leading in immunity, they know this is on everyones mind this year, and they are seeing a demand of people wanting revitalization programs, a type of holistic offering that boosts the immune system, while upgrading the mind and body notes Gibertoni. In response to COVID-19, we have introduced new elements to it, including immuno-fortifying ingredients, enhanced nutrition coaching and wellness solutions to help activate the immune function, Gibertoni says. In its one-week approach, Revitalization helps to combat stress and infections and to improve health related setbacks. The Revitalization has been carried out exclusively at CLP for nearly nine decades and does include the CLP Extract, containing biologically active substances, given in conjunction with bio-stimulants.

Recognizing that todays lifestyle can attack the immune system, CLPs MASTER DETOX program provide solutions. Stress, food treated with pesticides, overconsumption and demanding situations like the current one exposes us to a vast quantity of toxins which affect our bodies regeneration capabilities, which can lead to fatigue, digestive problems, allergies or a weakened immune system, says Gibertoni. And in the age of Covid, these negative factors are a need for the body to be eliminated of toxins and promote physiological balance. In this new MASTER DETOX week, we focus on a Cellular Genomic detoxification protocol, in line with our scientific approach, and as always on individual plans based on the four pillars of medical, nutrition, wellbeing and movement.

MONTREUX, SWITZERLAND - the Clinique La Prairie facility offers one-on-one services about the state ... [+] and health of your body and how to increase longevity.

Fashion and beauty start with wellbeing

Gibertoni gives a fitting example of how beauty is birthed out of a good wellbeing regiment.

The first: every health and wellbeing program is also about revealing beauty, because each creates a bespoke path to feel good inside and out. What you eat, your level of stress, your lifestyle habits, your sleep quality, your possible vitamins deficiencies, ... these are all factors very directly impacting beauty.

For example, nutrition based on antioxidants and nutrients that help reduce internal inflammation will support protection against free radical effects and promote hydration. Through individual consultations about longevity, DNA insights, nutrition and movement, and of course body and skin advanced treatments, many factors are addressed in a holistic way during the week program that the guest spends at CLP, leading to help restore healthy foundations and routines, and ultimately boosting radiance.

MONTREUX, SWITZERLAND - the Clinique La Prairie facility offers holistic treatments like massages.

For CLP, revitalization and their MASTER DETOX program has been tried and tested against a radical anti-aging and medical science, so their programs have been able to stand the test of time with their treatments, technologies and coaching that amplify a persons wellbeing.

The most top fashion model, designer, and fashion connoisseur cant have a successful run at fashion without a proper health and wellness regimen, and an occasional visit to a clinic like CLP if they can afford it.

The second dimension is about CLPs cutting-edge programs that focus specifically on anti-aging and regenerative medicine, with an integrative approach to rejuvenation. We help realize the personal journey to look, feel and live well, with cutting edge anti-aging aesthetics protocols for men and women, where all aspects of the body and face are taken into consideration.

MONTREUX, SWITZERLAND - the Clinique La Prairie facility

They do this through stem cell-based programs of the likes of their Beauty Stem Cells and Cell Boast Facelift, where an individuals own stem cells are clinically harvested and re-injected and they also revitalize the skin using natural resources from ones own body to regenerate and slow down aging. All of this results in restoring a persons youthful appearance. Non-invasive aesthetic medicine delivers the latest solutions in the advancing field of preventive and restorative aesthetics. And their 4-5-day beauty holistic programs utilize a holistic approach to beauty by using non-invasive technologies from CLPs anti-aging research.

We all know the latest runway collections are envogue and we all want to look fashionable and have our beauty top notch. What we do for our bodies, from what we put into it and how we treat it will result in our beauty and make us illuminate our various and unique fashion styles. CLP gets people there by going deeper and under the surface by identifying nutritional and lifestyle changes that their visitors need to implement into their lives. All of this leaves people looking radiant, sculpted, balanced and more youthful by the time they leave our facility, as Gibertoni points out and it provides long-lasting effects.

Find out more about Clinique La Prairie in Montreaux and stay tuned for their upcoming new location openings- here.

Read more from the original source:
How Clinique La Prairie Is Keeping Humanity Fashionably Healthy In The Age Of Covid - Forbes

Autologous Fat Grafting Market Scope Analysis 2019 to 2029 – The Think Curiouser

By Stem Cell Doctors

The Most Recent study on the Autologous Fat Grafting Market Research provides a profound comprehension of the various market dynamics like trends, drivers, the challenges, and opportunities. The report further elaborates on the micro and macro-economic elements that are predicted to shape the increase of the Autologous Fat Grafting market throughout the forecast period (2019-2029).

The introduced study elucidates the crucial indicators of Market growth which comes with a thorough analysis of this value chain, CAGR development, and Porters Five Forces Analysis. This data may enable readers to understand the quantitative growth parameters of this international industry that is Autologous Fat Grafting .

Analytical Insights Included from the Autologous Fat Grafting Market Report

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=2701

Autologous Fat Grafting Market Segmentation Assessment

The increase prospects of this market in various Regions are studied in the report together with details like the regulatory framework, political, and financial outlook of each region.

Competition Landscape

The four leading companies that account for the consolidation of the competition landscape of autologous fat grafting market, continue to represent a whopping 80% share in the revenues. Allergan, MicroAire, Alma Lasers, and Human Med are expected to primarily maintain their strategic focus on partnerships and acquisitions with smaller yet active players. The latter are typically specialized in the development of meniscus repair systems for treating meniscal scars. With this, leading companies operating in autologous fat grafting industry, are eyeing feasibility of entry in the meniscal scars treatment landscape. Increasing strategic tie-ups among manufacturers of systems & accessories, and recognized research institutions, aim to ensure sufficient device supply and superior post-sales service.

Manufacturers in the autologous fat grafting market are also investing efforts in introducing innovative products, to enhance their market shares. For instance, in 2019, Alma Lasers (Sisram Medical) announced the availability of BeautiFill as the novel laser-based technique for fat harvesting, while leveraging autologous fat to restore the volume to body or face. As cellular therapies are increasingly being perceived as mainstream therapeutic option, there has been a surge in demand for adipose derived stem cells (ADSC), which is potentially applicable in tissue engineering and regeneration. Additionally, a growing focus of leading players on introducing advanced systems & accessories is likely to extend applicability of their offerings, leveraging untapped opportunities in the autologous fat grafting market.

For more incisive insights into the autologous fat grafting market, request for the report sample

Key Factors Shaping Autologous Fat Grafting Market

For more intelligence on the autologous fat grafting market, request for the report sample

Key Challenges Facing Autologous Fat Grafting Market

Additional Insight

Biomaterial Research to Open Doors to Multiple Opportunities

Autologous fat grafting technique continues to witness frequent technical modifications. The adoption of autologous fat grafting as a technique to augment and regenerate deficient, irradiated, and aged subcutaneous soft tissue and skin, with minimal complication rate and donor-site morbidity, has grown spectacularly over the recent past. An approach garnering research interests for its potential role in enhancing volumetric retention of fat grafts, involves insertion of autologous platelet-rich fibrin (PRF) into graft tissues. A relevant study indicates PRF as a concentrate that may enhance the outcome of fat grafting for plastic surgery procedures. This newer biomaterial with several potential advantages, such as simpler preparation with no external additive, is likely to trigger new product developments in the autologous fat grafting market.

Autologous Fat Grafting Market Research Methodology

A patented research methodology and a holistic approach form the base of the insightful information provided in the autologous fat grafting market report. This study provides detailed information about the key factors associated with the growth of autologous fat grafting market and presents a systematic breakdown of the factors shaping the progress of market. Detailed primary and secondary research has been done to offer information about the historic and prospective analysis of fat grafting industry, with emphasis on the autologous fat grafting procedure. The report on autologous fat grafting market has also gone through several validation tunnels to guarantee the uniqueness of the insights and key growth influencers, covered in the report.

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=2701

The Report intends to eliminate the subsequent doubts regarding the Autologous Fat Grafting market:

Reasons To Choose Fact.MR:

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=2701

Read this article:
Autologous Fat Grafting Market Scope Analysis 2019 to 2029 - The Think Curiouser

X4 Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020

By Global News Feed

BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the third quarter ended September 30, 2020, and provide an update on recent business highlights, on November 5, 2020.

Read more:
X4 Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020

Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update

By Global News Feed

STOUGHTON, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.

Read more:
Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update

Shockwave Medical Announces VIVA20 Investor Update and Conference Call Discussing Third Quarter 2020 Results

By Global News Feed

SANTA CLARA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease will webcast an investor update at the virtual VIVA20 on Saturday, November 7 at 11:00 a.m. eastern time. Dr. William Gray, M.D., FACC, FSCAI, Chief of the Division of Cardiovascular Disease at Main Line Health, Wynnewood, PA; Co-Principal Investigator of DISRUPT PAD III will present the results of the PAD III study and then will be joined by Dr. Sarang Mangalmurti, M.D., Interventional Cardiologist and Endovascular Specialist, Bryn Mawr Hospital – Main Line, Doug Godshall, Chief Executive Officer of Shockwave and Keith Dawkins, Chief Medical Officer of Shockwave to discuss the results and answer questions from investors about the study.

Read the original:
Shockwave Medical Announces VIVA20 Investor Update and Conference Call Discussing Third Quarter 2020 Results

Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research

By Global News Feed

GUILFORD, Conn., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that John D. Vandermosten, CFA, Biotechnology Analyst of Zacks Small Cap Research division at Zacks Investment Research and his team (“Zacks”) has initiated analyst coverage on Bioasis Technologies Inc.

Read the original post:
Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research

→←